Connect Biopharma to Present at H.C. Wainwright Conference — Connect Biopharma Holdings Limited

Event summary

Connect Biopharma will participate in a fireside chat at the H.C. Wainwright 28th Annual Global Investment Conference on September 15, 2026, at 11:30 a.m. ET.
The presentation will be available via live webcast and archived for 90 days on the company's investor relations website.
Connect Biopharma is focused on treating inflammatory diseases, with its lead candidate, rademikibart, targeting IL-4Rα for asthma and COPD.
The company has an exclusive license agreement with Simcere Pharmaceutical for rademikibart in Greater China, with potential milestone payments up to $99 million and tiered royalties.

The big picture

Connect Biopharma's participation in the H.C. Wainwright conference underscores its efforts to engage with investors amid a competitive landscape in inflammatory disease treatments. The company's focus on rademikibart, coupled with its strategic partnership in Greater China, positions it within a growing market for targeted therapies in asthma and COPD. The success of its clinical trials and commercialization strategy will be critical in determining its long-term market position.

What we're watching

Clinical Progress: The pace at which Connect Biopharma advances its global clinical studies for rademikibart will determine its near-term valuation.
Commercialization Strategy: Whether the company can leverage its partnership with Simcere Pharmaceutical to successfully commercialize rademikibart in Greater China.
Investor Sentiment: How the upcoming presentation at the H.C. Wainwright conference will influence investor perception and potential funding opportunities.